Compare REFI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFI | VYGR |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.6M | 227.2M |
| IPO Year | 2021 | 2015 |
| Metric | REFI | VYGR |
|---|---|---|
| Price | $11.36 | $3.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 138.3K | ★ 511.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,857,628.00 | $10,135,000.00 |
| Revenue This Year | $17.47 | $34.04 |
| Revenue Next Year | $0.06 | $7.92 |
| P/E Ratio | $49.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.74 | $2.65 |
| 52 Week High | $14.97 | $5.55 |
| Indicator | REFI | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 47.93 |
| Support Level | $10.74 | $3.71 |
| Resistance Level | $12.45 | $4.39 |
| Average True Range (ATR) | 0.29 | 0.27 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 18.75 | 40.23 |
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.